New method for treating viral hepatitis will be implemented in Moldova

A new method for treating the viral hepatitis will be implemented in Moldova. In this regard, doctors specialised in treating this disease are being trained in applying this method within a scientific-practical symposium, organised in Chisinau on 15 and 16 February, by the Swiss Company “Hoffman-La Roche Ltd”, Info-Prim Neo reports. The Company’s manager general Ala Ciobanu told Info-Prim Neo that the new method for treating parenteral hepatitis B, C and D, which is a real danger to the health and life of patients, consists in applying new drugs PEGASYS and COPEGUS, which showed their efficiency in all categories of patients, including those have advanced forms of disease. As Ala Ciobanu says, the patients who are treated with PEGASYS in association with COPEGUS have obtained the highest rate, of 66%, regarding the Sustained Virological Response (SVR), related to the treatment for the viral chronicle hepatitis C. According to the cited source, PEGASYS is the first and the single Interferon Pegylat, used for treating viral hepatitis C, which obtained a sustained response rate of over 50% among the patients with genotype 1 or cirrhosis, diseases that are hardly treated. At the same time, 75% of the patients who obtain a SVR are cured at the end of the treatment. PEGASYS is used for treating viral hepatitis B, being the single medication suitable for the healing of this disease, Ala Ciobanu says. Moldovan doctors take part in the scientific-practical symposium, while two Romanian specialists – Florin Căruntu-Cercel and Marius Tănase are invited to make an exchange of experience. Requested by Info-Prim Neo, Marius Tănase stated that the new method of treating the viral hepatitis is being used in Romania for 2-3 years and reported exceptional results. According to the quoted source, the purpose of his arrival in Chisinau is to share with Moldovan colleagues the experience gained in the treatment for viral hepatitis using the new method. The situation concerning the prevalence of these maladies is almost identical, 4,4 in Romania, and 4,7 in Moldova. Head of Cathedra for infectious diseases from the Doctors’ Refresher Faculty, Victor Pântea told the agency that the treatment promoted by “Hoffman-La Roche ltd” is welcomed. At the moment, Pântea says, hepatitis with forms B, C and Delta, which mostly have a hidden and latent form evolution, is the biggest problem. Thus, out of 100 infected persons, 80 do not know they are sick until being diagnosed with cirrhosis, Pântea says. At the same time, these patients can become infection-sources for surgeons, surrounding people, contributing to the increase in number of viral hepatitis-infected persons. Leader in the field of pharmaceutics, Swiss Company “Hoffman-La Roche ltd” is based on a research, offering unique range of integrated therapeutic solutions aimed at detecting, preventing, diagnosing and treating the diseases. The Company is present in 150 countries of the world and has over 70 employees.